Probiotics, omega-3, vitamins and minerals in pediatrics: what the science says after thirteen clinical trials analyzed
A chronic diagnosis in a child changes the life of a family. It changes daily rhythms, priorities, the way parents look at the future. And it almost always changes the way they relate to medicine.
At some point, parents begin to look for something more. Something to sit alongside the therapy. Something that feels, in their perception, gentler, natural, part of daily life.
That is where the questions about supplements start. Probiotics, vitamins, omega-3, minerals. Someone suggests them, the pharmacy stocks them, a friend or an online group swears by them. But what does the actual science say?
A systematic review published in Frontiers in Pediatrics in January 2026 set out to answer, screening thirteen pediatric clinical trials from the last twenty years. The picture that emerges is richer than expected, and more nuanced.
Probiotics and microbiota: the most studied field in pediatrics
Most of the reviewed trials focus on probiotics. That is no accident. Over the past decade, the pediatric gut microbiota has become the gravitational center of a new, integrated pediatrics.
In autism spectrum disorder, a randomized trial in preschool children showed that adding a multi-strain probiotic to Applied Behavior Analysis (ABA) therapy improved ATEC scores and enriched Bifidobacterium and Lactobacillus in fecal composition.
In cystic fibrosis, a twelve-month trial with Lactobacillus rhamnosus GG produced striking results only in a specific subgroup: children who developed a bifidobacteria-dominated microbiota experienced fewer pulmonary exacerbations, better FEV1 and fewer antibiotic days.
On the type 1 diabetes front, ninety days of probiotic supplementation did not shift glycated hemoglobin, but did reduce fasting glucose. A small metabolic signal, though not a negligible one.
The picture shifts with irritable bowel syndrome. A multicenter trial with Bacillus clausii showed no superiority over placebo on the primary endpoint, with secondary effects limited to the constipation-predominant subtype.
Omega-3 in neurodevelopment: clear bioactivity, still uncertain clinical impact
Long-chain polyunsaturated fatty acids are structural components of neuronal membranes. The rationale for their use in pediatric neurology looks solid on paper. In practice, the data are more cautious.
In children with a recent autism diagnosis, six months of supplementation with EPA and DHA significantly raised red blood cell levels, confirming real bioavailability. In parallel, researchers observed a reduction in IL-2, a key inflammatory cytokine.
Clinically, however, target behaviors did not show robust short-term improvements. A recurring pattern in neurotrophic research: the biological signal is there, but clinical translation stays slow and uneven.
A notable data point in pediatric rheumatology: in a pilot study with Kre-Celazine®, a combination of cetylated fatty acids and omega-3, children with juvenile idiopathic arthritis showed preliminary reductions in pain and inflammation after twelve weeks.
Vitamins and minerals: small molecules, tangible effects
Micronutrient deficiencies are common in chronic pediatric conditions. Altered absorption, increased metabolic demand, restrictive diets: three factors that frequently overlap in cystic fibrosis, chronic asthma and autoimmune diseases.
Here are the strongest signals emerging from the review:
- Enteral vitamin A in preterm infants with bronchopulmonary dysplasia: reduction in severity depending on dose and timing, on a cohort of more than 800 patients.
- Oral zinc in cystic fibrosis: fewer and shorter recurrent respiratory infections.
- Oral magnesium in cystic fibrosis: improvement of clinical, functional and nutritional parameters in a controlled crossover trial.
- Oral glutathione in autism: biochemical changes in the redox profile without clear clinical translation.
The industry takeaway is clear: targeted pediatric formulations with age-calibrated dosages and verified bioavailability represent an area with real scientific and regulatory room to grow.
One approach to avoid: the lesson of DMSA chelation
Not everything marketed as a supplement actually is one. The review dedicates critical space to DMSA, a chelating agent still used in some settings for autism on the hypothetical basis of heavy metal intoxication.
The findings are unambiguous: some biochemical changes, no consistent clinical benefit, and significant risks such as depletion of essential minerals and systemic adverse effects. Outside documented toxicological contexts, this approach has no clinical justification today.
A useful reminder for anyone working in the supplement supply chain: the perception of “natural” does not translate into safety, especially when the target population is pediatric.
What the pediatric nutraceutical of tomorrow needs
Why are the review’s results so nuanced? The answer is methodological. Small samples, short follow-ups, heterogeneous endpoints, no stratification by biological profile. The same weaknesses appear across too many pediatric trials.
The future of supplementation in childhood runs through three converging directions:
- Predictive biomarkers to identify truly responsive subgroups, starting with baseline microbiota composition.
- Longer multicenter trials with standardized endpoints such as hospitalizations, respiratory function and objective neurocognitive parameters.
- Personalized formulations by age range, palatable pediatric matrices, and documented long-term safety profiles.
Companies developing pediatric supplements on a contract manufacturing basis face a growing market, but also a higher level of technical and regulatory responsibility than in other segments. Families demand more, pediatricians demand evidence, regulators demand transparency.
The pediatric nutraceutical of the next decade will not be built on generic products transferred from the adult segment. It will be built on formulations designed from the start for a specific audience, backed by studies that demonstrate not only bioactivity but real clinical value.
If your company is interested in developing pediatric nutraceutical formulations based on probiotics, omega-3, vitamins or minerals
Source: Inchingolo A.D. et al., “Dietary and complementary oral supplements for the management of chronic diseases in children: a systematic review”, Frontiers in Pediatrics, 13:1710200, 2026. DOI: 10.3389/fped.2025.1710200
